nodes	percent_of_prediction	percent_of_DWPC	metapath
Lornoxicam—PTGS2—Triamcinolone—multiple sclerosis	0.389	0.396	CbGbCtD
Lornoxicam—PTGS2—Betamethasone—multiple sclerosis	0.334	0.34	CbGbCtD
Lornoxicam—PTGS2—Dexamethasone—multiple sclerosis	0.194	0.198	CbGbCtD
Lornoxicam—CYP2C9—Dexamethasone—multiple sclerosis	0.066	0.0671	CbGbCtD
Lornoxicam—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.0024	0.159	CbGdCrCtD
Lornoxicam—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.00236	0.156	CbGdCrCtD
Lornoxicam—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.00236	0.156	CbGdCrCtD
Lornoxicam—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.0023	0.153	CbGdCrCtD
Lornoxicam—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.00145	0.0958	CbGdCrCtD
Lornoxicam—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.00142	0.0943	CbGdCrCtD
Lornoxicam—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.00142	0.0943	CbGdCrCtD
Lornoxicam—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.00139	0.0921	CbGdCrCtD
Lornoxicam—PTGS2—S1P1 pathway—S1PR1—multiple sclerosis	0.00013	0.0663	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTPRK—multiple sclerosis	9.89e-05	0.0505	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TBX21—multiple sclerosis	6.38e-05	0.0325	CbGpPWpGaD
Lornoxicam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	5.75e-05	0.0293	CbGpPWpGaD
Lornoxicam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	5.75e-05	0.0293	CbGpPWpGaD
Lornoxicam—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	5.75e-05	0.0293	CbGpPWpGaD
Lornoxicam—PTGS1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	5.63e-05	0.0287	CbGpPWpGaD
Lornoxicam—PTGS1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	5.63e-05	0.0287	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CBLB—multiple sclerosis	4.68e-05	0.0239	CbGpPWpGaD
Lornoxicam—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	4.56e-05	0.0233	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—multiple sclerosis	3.79e-05	0.0194	CbGpPWpGaD
Lornoxicam—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	3.65e-05	0.0186	CbGpPWpGaD
Lornoxicam—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	3.65e-05	0.0186	CbGpPWpGaD
Lornoxicam—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	3.6e-05	0.0184	CbGpPWpGaD
Lornoxicam—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	3.6e-05	0.0184	CbGpPWpGaD
Lornoxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—multiple sclerosis	3.14e-05	0.016	CbGpPWpGaD
Lornoxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—multiple sclerosis	3.05e-05	0.0156	CbGpPWpGaD
Lornoxicam—PTGS1—Biological oxidations—CYP27B1—multiple sclerosis	2.99e-05	0.0153	CbGpPWpGaD
Lornoxicam—PTGS1—Biological oxidations—CYP24A1—multiple sclerosis	2.99e-05	0.0153	CbGpPWpGaD
Lornoxicam—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	2.96e-05	0.0151	CbGpPWpGaD
Lornoxicam—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	2.96e-05	0.0151	CbGpPWpGaD
Lornoxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—multiple sclerosis	2.8e-05	0.0143	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—MBP—multiple sclerosis	2.73e-05	0.0139	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—multiple sclerosis	2.61e-05	0.0133	CbGpPWpGaD
Lornoxicam—PTGS1—Overview of nanoparticle effects—TNF—multiple sclerosis	2.11e-05	0.0108	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—AQP4—multiple sclerosis	2.07e-05	0.0105	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—multiple sclerosis	2.03e-05	0.0104	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—multiple sclerosis	1.97e-05	0.0101	CbGpPWpGaD
Lornoxicam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	1.88e-05	0.0096	CbGpPWpGaD
Lornoxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—multiple sclerosis	1.84e-05	0.00942	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—multiple sclerosis	1.81e-05	0.00923	CbGpPWpGaD
Lornoxicam—PTGS2—S1P1 pathway—MAPK1—multiple sclerosis	1.76e-05	0.00898	CbGpPWpGaD
Lornoxicam—PTGS1—Overview of nanoparticle effects—IL6—multiple sclerosis	1.7e-05	0.00869	CbGpPWpGaD
Lornoxicam—PTGS2—Overview of nanoparticle effects—TNF—multiple sclerosis	1.67e-05	0.00855	CbGpPWpGaD
Lornoxicam—PTGS2—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	1.65e-05	0.00844	CbGpPWpGaD
Lornoxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—multiple sclerosis	1.64e-05	0.00837	CbGpPWpGaD
Lornoxicam—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	1.57e-05	0.00802	CbGpPWpGaD
Lornoxicam—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	1.57e-05	0.00802	CbGpPWpGaD
Lornoxicam—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	1.55e-05	0.00791	CbGpPWpGaD
Lornoxicam—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	1.55e-05	0.00791	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—CCR2—multiple sclerosis	1.43e-05	0.00731	CbGpPWpGaD
Lornoxicam—PTGS2—Overview of nanoparticle effects—IL6—multiple sclerosis	1.35e-05	0.0069	CbGpPWpGaD
Lornoxicam—PTGS1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.27e-05	0.00646	CbGpPWpGaD
Lornoxicam—PTGS1—Selenium Micronutrient Network—ICAM1—multiple sclerosis	1.26e-05	0.00641	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—multiple sclerosis	1.19e-05	0.00609	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—CXCL10—multiple sclerosis	1.19e-05	0.00608	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	1.15e-05	0.00586	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	1.15e-05	0.00586	CbGpPWpGaD
Lornoxicam—PTGS1—Selenium Micronutrient Network—CCL2—multiple sclerosis	1.12e-05	0.00574	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—BDNF—multiple sclerosis	1.07e-05	0.00546	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—multiple sclerosis	1.06e-05	0.00541	CbGpPWpGaD
Lornoxicam—PTGS1—Selenium Micronutrient Network—ALB—multiple sclerosis	1.05e-05	0.00535	CbGpPWpGaD
Lornoxicam—PTGS2—Selenium Micronutrient Network—ICAM1—multiple sclerosis	9.98e-06	0.00509	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—IL4—multiple sclerosis	9.93e-06	0.00507	CbGpPWpGaD
Lornoxicam—PTGS1—Selenium Micronutrient Network—IFNG—multiple sclerosis	9.56e-06	0.00488	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	9.11e-06	0.00465	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	9.11e-06	0.00465	CbGpPWpGaD
Lornoxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	9.06e-06	0.00462	CbGpPWpGaD
Lornoxicam—PTGS2—Selenium Micronutrient Network—CCL2—multiple sclerosis	8.93e-06	0.00456	CbGpPWpGaD
Lornoxicam—PTGS2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	8.86e-06	0.00452	CbGpPWpGaD
Lornoxicam—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	8.67e-06	0.00442	CbGpPWpGaD
Lornoxicam—PTGS1—Selenium Micronutrient Network—IL1B—multiple sclerosis	8.53e-06	0.00435	CbGpPWpGaD
Lornoxicam—PTGS2—Selenium Micronutrient Network—ALB—multiple sclerosis	8.32e-06	0.00425	CbGpPWpGaD
Lornoxicam—PTGS2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	8.26e-06	0.00421	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—TLR4—multiple sclerosis	8.23e-06	0.0042	CbGpPWpGaD
Lornoxicam—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.21e-06	0.00419	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—ICAM1—multiple sclerosis	7.89e-06	0.00403	CbGpPWpGaD
Lornoxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—multiple sclerosis	7.72e-06	0.00394	CbGpPWpGaD
Lornoxicam—PTGS2—C-MYB transcription factor network—CD4—multiple sclerosis	7.61e-06	0.00388	CbGpPWpGaD
Lornoxicam—PTGS2—Selenium Micronutrient Network—IFNG—multiple sclerosis	7.59e-06	0.00387	CbGpPWpGaD
Lornoxicam—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	7.27e-06	0.00371	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism—SRM—multiple sclerosis	7.26e-06	0.0037	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—CCL2—multiple sclerosis	7.06e-06	0.0036	CbGpPWpGaD
Lornoxicam—PTGS2—Selenium Micronutrient Network—IL1B—multiple sclerosis	6.77e-06	0.00346	CbGpPWpGaD
Lornoxicam—PTGS1—Biological oxidations—POMC—multiple sclerosis	6.72e-06	0.00343	CbGpPWpGaD
Lornoxicam—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.65e-06	0.0034	CbGpPWpGaD
Lornoxicam—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	6.23e-06	0.00318	CbGpPWpGaD
Lornoxicam—PTGS1—Selenium Micronutrient Network—TNF—multiple sclerosis	6.19e-06	0.00316	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.03e-06	0.00308	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.03e-06	0.00308	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—IFNG—multiple sclerosis	6e-06	0.00306	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism—SRM—multiple sclerosis	5.76e-06	0.00294	CbGpPWpGaD
Lornoxicam—PTGS2—C-MYB transcription factor network—MYC—multiple sclerosis	5.47e-06	0.00279	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—IL1B—multiple sclerosis	5.35e-06	0.00273	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—IL2—multiple sclerosis	5.33e-06	0.00272	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism—CYP27B1—multiple sclerosis	5.11e-06	0.00261	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism—CYP24A1—multiple sclerosis	5.11e-06	0.00261	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—MMP9—multiple sclerosis	5.05e-06	0.00258	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5e-06	0.00255	CbGpPWpGaD
Lornoxicam—PTGS1—Selenium Micronutrient Network—IL6—multiple sclerosis	4.99e-06	0.00255	CbGpPWpGaD
Lornoxicam—PTGS2—Selenium Micronutrient Network—TNF—multiple sclerosis	4.91e-06	0.00251	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism—GPC5—multiple sclerosis	4.68e-06	0.00239	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—GPC5—multiple sclerosis	4.43e-06	0.00226	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	4.17e-06	0.00213	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	4.16e-06	0.00212	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	4.08e-06	0.00208	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism—CYP27B1—multiple sclerosis	4.06e-06	0.00207	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism—CYP24A1—multiple sclerosis	4.06e-06	0.00207	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.97e-06	0.00202	CbGpPWpGaD
Lornoxicam—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	3.97e-06	0.00202	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	3.89e-06	0.00198	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism—RRM1—multiple sclerosis	3.87e-06	0.00198	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism—SRM—multiple sclerosis	3.81e-06	0.00195	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism—GPC5—multiple sclerosis	3.71e-06	0.00189	CbGpPWpGaD
Lornoxicam—CYP2C9—Biological oxidations—POMC—multiple sclerosis	3.54e-06	0.0018	CbGpPWpGaD
Lornoxicam—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	3.14e-06	0.0016	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism—RRM1—multiple sclerosis	3.08e-06	0.00157	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.01e-06	0.00153	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—RPL5—multiple sclerosis	2.88e-06	0.00147	CbGpPWpGaD
Lornoxicam—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.84e-06	0.00145	CbGpPWpGaD
Lornoxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.83e-06	0.00144	CbGpPWpGaD
Lornoxicam—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.78e-06	0.00142	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—SLC11A1—multiple sclerosis	2.76e-06	0.00141	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.69e-06	0.00137	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.69e-06	0.00137	CbGpPWpGaD
Lornoxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.64e-06	0.00135	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.63e-06	0.00134	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.58e-06	0.00132	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism—GPC5—multiple sclerosis	2.46e-06	0.00125	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.39e-06	0.00122	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.35e-06	0.0012	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism—BCHE—multiple sclerosis	2.23e-06	0.00114	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—CD28—multiple sclerosis	2.2e-06	0.00112	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.05e-06	0.00105	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism—RRM1—multiple sclerosis	2.04e-06	0.00104	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.87e-06	0.000954	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism—BCHE—multiple sclerosis	1.77e-06	0.000901	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.58e-06	0.000806	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—CD86—multiple sclerosis	1.57e-06	0.000803	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—CCR5—multiple sclerosis	1.39e-06	0.000712	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—HLA-A—multiple sclerosis	1.36e-06	0.000694	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.36e-06	0.000693	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism—APOE—multiple sclerosis	1.34e-06	0.000683	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—APOE—multiple sclerosis	1.27e-06	0.000648	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.24e-06	0.000632	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.17e-06	0.000597	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism—POMC—multiple sclerosis	1.15e-06	0.000587	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—CD80—multiple sclerosis	1.15e-06	0.000585	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism—APOE—multiple sclerosis	1.06e-06	0.000542	CbGpPWpGaD
Lornoxicam—PTGS1—Metabolism—ALB—multiple sclerosis	1.05e-06	0.000535	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—TYK2—multiple sclerosis	9.68e-07	0.000494	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism—POMC—multiple sclerosis	9.13e-07	0.000466	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—CD4—multiple sclerosis	8.76e-07	0.000447	CbGpPWpGaD
Lornoxicam—PTGS2—Metabolism—ALB—multiple sclerosis	8.32e-07	0.000425	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism—APOE—multiple sclerosis	7.04e-07	0.000359	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—STAT3—multiple sclerosis	6.78e-07	0.000346	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—MYC—multiple sclerosis	6.3e-07	0.000322	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—TGFB1—multiple sclerosis	6.29e-07	0.000321	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—MAPK1—multiple sclerosis	6.16e-07	0.000315	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism—POMC—multiple sclerosis	6.05e-07	0.000309	CbGpPWpGaD
Lornoxicam—CYP2C9—Metabolism—ALB—multiple sclerosis	5.51e-07	0.000281	CbGpPWpGaD
Lornoxicam—PTGS2—Disease—IL6—multiple sclerosis	4.74e-07	0.000242	CbGpPWpGaD
